NeuExcell Therapeutics Reports Encouraging Clinical Results with World’s First In Situ Conversion Therapy for Malignant GliomaSINGAPORE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- NeuExcell Therapeutics announced encouraging clinical results of NXL-004, the world’s first in situ conversion gene therapy for malignant glioma. The data were presented at the ESMO Asia Congress 2025, December 5–7 in Singapore.
